ARQULE
ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs technologies, such as its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs. The Company's product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ 197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcrip... tion Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin).
ARQULE
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
1993-01-01
Address:
Woburn, Massachusetts, United States
Country:
United States
Website Url:
http://www.arqule.com
Total Employee:
11+
Status:
Closed
Contact:
781-994-0300
Email Addresses:
[email protected]
Total Funding:
9.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF LetsEncrypt Domain Not Resolving Nginx Microsoft Exchange Online IPv6 Microsoft Azure DNS Cloudflare JS
Similar Organizations
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
Axcella
Axcella is a biotechnology company providing therapeutics development solutions.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Imvax
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
Novavax
Novavax is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines.
SpeciGen Inc.
SpeciGen is a developmental biotechnology company, engages in the design and development of protein cages that contain samples of cancer.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2003-07-18 | Cyclis Pharmaceuticals | Cyclis Pharmaceuticals acquired by ArQule | 25 M USD |
| 2001-01-22 | Camitro | Camitro acquired by ArQule | 106.2 M USD |
Investors List
Pontifax
Pontifax investment in Post-IPO Equity - ArQule
Atlas Venture
Atlas Venture investment in Seed Round - ArQule
Official Site Inspections
http://www.arqule.com Semrush global rank: 7.73 M Semrush visits lastest month: 437
Unable to get host informations!!!
More informations about "ArQule" on Search Engine
Merck to Acquire ArQule, Advancing Leadership in …
Dec 9, 2019 ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. ArQule’s …See details»
ArQule - Crunchbase Company Profile & Funding
ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs technologies, such as its …See details»
Merck Completes Acquisition of ArQule - Merck.com
January 16, 2020 8:34 am ET. KENILWORTH, N.J.– ( BUSINESS WIRE )–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the …See details»
Merck Begins Tender Offer to Acquire ArQule - Merck.com
Dec 17, 2019 KENILWORTH, N.J.– ( BUSINESS WIRE )–Merck (NYSE: MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, …See details»
Merck closes $2.7bn acquisition of biopharmaceutical …
Jan 17, 2020 News. Merck closes $2.7bn acquisition of biopharmaceutical firm ArQule. Merck (MSD) has completed its previously announced …See details»
ArQule To Be Acquired By Merck For $2.7B - Yahoo Finance
Dec 9, 2019 MRK. Merck (NYSE: MRK) will acquire ArQule, Inc. (NASDAQ: ARQL) for $20 per share in cash for an approximate total equity value of $2.7 billion. ArQule is a …See details»
Merck to Buy ArQule for $2.7B to Boost Cancer Portfolio - Yahoo …
Dec 10, 2019 Zacks Equity Research. December 10, 2019. Merck & Co., Inc. MRK announced that it has entered into a definitive agreement to acquire Massachusetts …See details»
ArQule to be Acquired by Merck, Advancing Leadership in Oncology
Dec 10, 2019 Merck, known as MSD outside the United States and Canada, and ArQule, Inc. announced that the companies have entered into a definitive agreement under which …See details»
ArQule Company Profile - Office Locations, Competitors, …
Jan 16, 2020 ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and certain rare diseases. The …See details»
ArQule wanted a partner. Merck wanted control.
By Angus Liu Dec 19, 2019 11:56am. chronic lymphocytic leukemia M&A Array BioPharma Eli Lilly. Initial talks for co-development of BTK inhibitor ARQ 531 helped ArQule land a …See details»
Merck to Acquire ArQule, Advancing Leadership in Oncology
Dec 9, 2019 ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. ArQule’s …See details»
Merck to Acquire ArQule, Advancing Leadership in Oncology
KENILWORTH, N.J. & BURLINGTON, Mass.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and ArQule, Inc. (Nasdaq: …See details»
Oncology Merck to Acquire ArQule, Advancing Leadership in
States and Canada, and ArQule, Inc. (Nasdaq: ARQL) today announced that the companies have entered into a denitive agreement under which Merck, through a subsidiary, will …See details»
ArQule, Inc. and Daiichi Sankyo Co Ltd. Enter Into Strategic R&D ...
Nov 10, 2008 ArQule and Daiichi Sankyo have entered into a research collaboration, exclusive license and co-commercialization agreement under which ArQule will apply its …See details»
Merck Completes Acquisition of ArQule - s2.q4cdn.com
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the successful completion of the cash …See details»
ArQule - Contacts, Employees, Board Members, Advisors
ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs.See details»
ArQule, Inc. | VentureRadar
Founded in 2011. Listed Company. Develops innovative cancer therapies targeting molecular aspects of human cancers, aiming to create selective, well-tolerated …See details»
Merck to Acquire ArQule, Advancing Leadership in Oncology
Dec 9, 2019 ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. ArQule’s …See details»
ArQule, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Apr 1, 2024 10-50. | NASDAQ: ARQL |. www.arqule.com. Last update 01 Apr 2024. Overview. Pipeline. Deal. Translational Medicine. Profit. Grant & Funding (NIH) …See details»
ARQULE AND DAIICHI-SANKYO ENTER INTO STRATEGIC …
Nov 10, 2008 ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's …See details»